[{"orgOrder":0,"company":"Aspen Pharmacare Holdings","sponsor":"Acino Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2021","type":"Acquisition","leadProduct":"Esomeprazole Magnesium","moa":"Potassium-transporting ATPase","graph1":"Gastroenterology","graph2":"Approved","graph3":"Aspen Pharmacare Holdings","amount2":0.12,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0.12,"dosageForm":"Tablet","sponsorNew":"Aspen Pharmacare Holdings \/ Acino","highestDevelopmentStatusID":"12","companyTruncated":"Aspen Pharmacare Holdings \/ Acino"},{"orgOrder":0,"company":"Granules India Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Granules India Limited","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Granules India Limited \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Granules India Limited \/ Not Applicable"},{"orgOrder":0,"company":"Towa Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Towa Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule, Delayed Release","sponsorNew":"Towa Pharmaceutical \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Towa Pharmaceutical \/ Not Applicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"Esomeprazole Magnesium","moa":"","graph1":"Gastroenterology","graph2":"Approved","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"","sponsorNew":"Glenmark Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Glenmark Pharmaceuticals \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for Esomeprazole

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Esomeprazole magnesium delayed-release capsules is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

                          Brand Name : Nexium-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          October 19, 2023

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Granules India

                          02

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Study Phase : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : Esomeprazole magnesium hydrate capsules is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

                          Brand Name : Esomeprazole-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          February 14, 2024

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Towa Pharmaceutical

                          03

                          Details : The transaction includes Trustan, Altosec, Zuvamor, Ciavor, Grantryl and Aspen Granisetron brands. To secure uninterrupted patient access to these medicines, the parties have also signed a manufacturing and supply agreement.

                          Brand Name : Trustan

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          October 22, 2021

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Acino Pharma

                          Deal Size : $119.4 million

                          Deal Type : Acquisition

                          Aspen API Comapny Banner

                          04

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : Nexium-Generic (esomeprazole magnesium) is a proton pump inhibitor indicated for the treatment of gastroesophageal reflux disease and NSAID-associated gastric ulcer.

                          Brand Name : Nexium-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 12, 2024

                          Lead Product(s) : Esomeprazole Magnesium

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Approved

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank